Last updated on April 2019

A Study to Evaluate the Safety Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B

Brief description of study

This randomized study will be conducted in two parts to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931. Part 1 will include only healthy participants and Part 2 will include only participants with chronic hepatitis B (CHB). Part 1 is an adaptive, single-ascending dose study with an adaptive dose-escalating schedule to determine the best dose to be evaluated in participants with CHB. Part 2 is an adaptive, parallel multiple-dose study comprised of two sub-parts which will be used to further refine the dose and dosing regimen.

Clinical Study Identifier: NCT03038113

Contact Investigators or Research Sites near you

Start Over

Prince of Wales Hospital

Shatin, New Territories, Hong Kong
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.